-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

617A.O2.6 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics

Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Acute Myeloid Malignancies, AML, Biological therapies, Translational Research, Clinical Research, Combination therapy, Diseases, real-world evidence, Therapies, Immunotherapy, Myeloid Malignancies, Natural Killer (NK) Cell Therapies
Saturday, December 9, 2023: 2:00 PM-3:30 PM
Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)
Melinda Ann Biernacki, MD, Fred Hutchinson Cancer Center and Tanja A. Gruber, MD, PhD, Stanford University School of Medicine
No relevant conflicts of interest to declare.
2:00 PM

Véronique Lisi1*, Banafsheh Khakipoor, PhD2*, Azer Farah, PhD2*, Marie-Eve Bordeleau, PhD3*, Eric Audemard, PhD3*, Arnaud Metois, MSc3*, Louis Theret, PhD3*, Jean-François Spinella, PhD3*, Jalila Chagraoui, PhD3*, Ossama Moujaber, PhD3*, Laure Mallinger3*, Isabel Boivin3*, Nadine Mayotte, MS3*, Azadeh Hajmirza, PhD3*, Eric Bonneil, PhD3*, Francois Béliveau, PhD4*, Albert Feghali3*, Geneviève Boucher3*, Patrick Gendron3*, Frederic Barabe, MD5, Sebastien Lemieux, PhD3*, Guillaume Richard-Carpentier, MD, FRCPC6, Josée Hébert, MD3*, Philippe Roux, PhD3*, Guy Sauvageau, MD/PhD3 and Vincent-Philippe Lavallee, MD/PhD2

1Centre Hospitalier Universitaire Sainte-Justine Research Center, Montreal, QC, Canada
2CHU Sainte-Justine, Montreal, QC, Canada
3Institut de recherche en Immunologie et Cancer, Université de Montréal, Montreal, QC, Canada
4Banque de cellules leucémiques du Québec, Montréal, QC, Canada
5Hôpital de l'Enfant-Jésus, Division of Hematology and Medical Oncology, CHU de Québec - Université Laval, Québec, QC, Canada
6Princess Margaret Cancer Center, Toronto, ON, CAN

2:15 PM

Amanda Halfond, MSc1*, Matthew H Ung, PhD2*, Julia Etchin, PhD1*, Yonina Keschner1*, Julia DiFazio1*, Alyssa Pyclik1*, Guy Mundelboim1*, Gary Ge, PhD1*, John Lydeard, PhD1* and Tirtha Chakraborty, PhD1*

1Vor Biopharma, Cambridge, MA
2Quantitative Biology, Vor Biopharma, Cambridge, MA

2:30 PM

Eduardo Sabino Magalhaes, MD1*, Stefan Hubner2*, Brandon D. Brown, MD3*, Yihua Qiu4* and Steven M. Kornblau, MD4

1Department of Ageing Biology/ERIBA, University Medical Center Groningen, Groningen, Netherlands
2John Sealy School of Medicine, The University of Texas Medical Branch (UTMB), Galveston, TX
3Department of Pediatrics, MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

2:45 PM

Nastassja Scheidegger, MD1,2,3*, Gabriela Alexe, PhD2,3*, Delan Khalid2,3*, Rhonda E Ries, MA4*, Jim Wang, MS5*, Todd A. Alonzo, PhD5,6*, Jennifer Perry, PhD2*, Scott A Armstrong, MD, PhD7, Soheil Meshinchi, MD, PhD8, Yana Pikman, MD2,3 and Kimberly Stegmaier, MD2,9

1Department of Pediatric Oncology, Children’s University Hospital of Zurich, Zurich, Switzerland
2Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA
3The Broad Institute of MIT and Harvard, Cambridge, MA
4Translational Sciences and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA
5Children's Oncology Group, Monrovia, CA
6Univ. of Southern California Keck School of Med., Monrovia, CA
7Pediatric Oncology, Dana-Farber Cancer Institute, Boston
8Translational Sciences and Therapeutics, Fred Hutchinson Cancer Research Center, Seattle, WA
9The Broad Institute of MIT and Harvard, Cambridge

3:00 PM

Kishan Bellamkonda, PhD1*, Ramprasad Ramakrishnan, PhD1*, Somadri Ghosh2*, Katrin Reinbach1* and Marcus Järås, PhD1*

1Division of Clinical Genetics, Lund University, Lund, Skåne, Sweden
2Division of Clinical Genetics, Lund University, Lund, Sweden

3:15 PM

Fanny Gonzales, MD, PhD1,2, Pauline Peyrouze, MS1*, Thomas Boyer, MD, PhD1*, Soizic Guihard, PhD1*, Francois Sevrin, MD1*, Djohana Laurent, MS1*, Adriana Plesa, MD3*, Adeline Barthelemy, PhD1*, Antonino Bongiovanni, PhD4*, Claude Preudhomme, PharmD, PhD1,5*, Nicolas Duployez, PharmD, PhD1,5*, Celine Berthon, MD, PhD1*, Christophe Roumier, PharmD1,5* and Meyling H Cheok, PharmD, PhD1*

1ONCOLILLE - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Univ. Lille, CHU Lille, IRCL, ONCOLILLE, CNRS-UMR9020, Inserm-U1277, Lille, France
2Paediatric Haematology Department, CHU Lille, Lille, France
3Laboratory of Hematology, Hospices Civils de Lyon, Lyon, France
4Univ. Lille, CNRS UMR 8204, Inserm U1019, CHU Lille, Institut Pasteur de Lille - CIIL - Center for Infection and Immunity of Lille, Lille, France
5Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France

*signifies non-member of ASH